e-Therapeutics plc Begins Phase I Study Of Oral Formulation Of Anti-Cancer Compound ETS2101 With Healthy Volunteers

Published: Feb 10, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OXFORD & NEWCASTLE, England--(BUSINESS WIRE)--e-Therapeutics plc (AIM:ETX) announced today that it has dosed the first healthy volunteer in a newly initiated Phase I clinical trial with an oral formulation of its anti-cancer compound, ETS2101. The Phase I study will employ escalating doses of ETS2101 given orally in healthy subjects to evaluate the pharmacokinetics (PK) and oral bioavailability of ETS2101 in this form. The trial, which is conducted in the UK, is expected to recruit 24 healthy volunteers and is anticipated to complete in Q4 2014.

Help employers find you! Check out all the jobs and post your resume.

Back to news